The Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 aims to ensure that biomedical products and services developed with federal funding are sold at reasonable prices. The main goal is to protect taxpayers and patients from high costs associated with drugs and medical services that benefit from public investment. The key provisions of this legislation require that any federally funded research and development agreements include a clause mandating reasonable pricing for the resulting biomedical products or services.